Company profile
Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BETAINE | approved | — | 0 | — |
| Hydrocortisone | approved | — | 4 | approved |
| MECASERMIN | approved | — | 0 | — |
| NITISINONE | approved | — | 0 | — |
| Propranolol hydrochloride | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (0)
No records yet.
FDA applications (8)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 210508 | ANDA | ETON PHARMACEUTICALS INC | ||||
Loading… | ||||||
| ANDA 216201 | ANDA | ETON PHARMACEUTICALS INC | ||||
Loading… | ||||||
| BLA 021839 | BLA | Eton Pharmaceuticals, Inc. | ||||
Loading… | ||||||
| NDA 020458 | NDA | ETON PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 205410 | NDA | ETON PHARMACEUTICALS INC | ||||
Loading… | ||||||